30 October 2024 in International Immunopharmacology
18 October 2024 in Transfusion Medicine Reviews
B-thalassemia and sickle cell disease are among the most prevalent genetic blood disorders globally. These conditions arise from mutations in the B-globin gene, leading to defective hemoglobin production and resulting in anemia. Current treatments include y-globin inducers (eg, Hydroxyurea), blood transfusions, iron chelation therapy, and bone marrow transplantation. Recently approved disease-modifying agents and promising gene therapies offer hope, yet their broad application is constrained by scalability challenges. Traditionally, research and development for B-globinopathies have focused on y-globin induction. However, the s-globin variant, which is active during early embryonic development and subsequently silenced prenatally, was once considered noninducible by postnatal pharmacological means. Recent studies indicate that, akin to y-globin, enhancing s-globin expression could compensate for impaired B-globin synthesis, potentially ameliorating the clinical manifestations of B-globinopathies. This review critically examines the viability of s-globin induction as a therapeutic strategy for B-thalassemia and sickle cell diseases. It also delves into the burgeoning research on the mechanisms governing s-globin silencing and its pharmacological reactivation. We conclude with a discussion of prospective research directions and drug development initiatives aimed at exploiting s-globin's therapeutic promise. (c) 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
26 September 2022 in arXiv
Real-time biosignal processing on wearable devices has attracted worldwide attention for its potential in healthcare applications. However, the requirement of low-area, low-power and high adaptability to different patients challenge conventional algorithms and hardware platforms. In this design, a compact online learning neuromorphic hardware architecture with ultra-low power consumption designed explicitly for biosignal processing is proposed. A trace-based Spiking-Timing-Dependent-Plasticity (STDP) lgorithm is applied to realize hardware-friendly online learning of a single-layer excitatory-inhibitory spiking neural network. Several techniques, including event-driven architecture and a fully optimized iterative computation approach, are adopted to minimize the hardware utilization and power consumption for the hardware implementation of online learning. Experiment results show that the proposed design reaches the accuracy of 87.36% and 83% for the Mixed National Institute of Standards and Technology database (MNIST) and ECG classification. The hardware architecture is implemented on a Zynq-7020 FPGA. Implementation results show that the Look-Up Table (LUT) and Flip Flops (FF) utilization reduced by 14.87 and 7.34 times, respectively, and the power consumption reduced by 21.69% compared to state of the art.